CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −96 | $450.09 | $43K | 25,128 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −129 | $451.51 | $58K | 24,999 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −368 | $455.24 | $168K | 24,631 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −364 | $456.25 | $166K | 24,267 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −262 | $457.39 | $120K | 24,005 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −794 | $458.41 | $364K | 23,211 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −622 | $459.89 | $286K | 22,589 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −707 | $460.84 | $326K | 21,882 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −323 | $461.96 | $149K | 21,559 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −295 | $463.08 | $137K | 21,264 |
| 2025-11-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Option exercise · Stock Option (right to buy) 10b5-1 | −8,161 | 839 | ||
| 2025-11-13 | Greenstreet Yvonne Chief Executive Officer | Option exercise 10b5-1 | +10,000 | $119.13 | $1.2M | 75,409 |
| 2025-11-13 | Greenstreet Yvonne Chief Executive Officer | Sale 10b5-1 | −654 | $447.73 | $293K | 74,755 |
| 2025-11-13 | Greenstreet Yvonne Chief Executive Officer | Sale 10b5-1 | −1,013 | $448.76 | $455K | 73,742 |
| 2025-11-13 | Greenstreet Yvonne Chief Executive Officer | Sale 10b5-1 | −1,477 | $450.02 | $665K | 72,265 |
| 2025-11-13 | Greenstreet Yvonne Chief Executive Officer | Sale 10b5-1 | −2,218 | $450.69 | $1000K | 70,047 |
| 2025-11-13 | Greenstreet Yvonne Chief Executive Officer | Sale 10b5-1 | −1,702 | $451.94 | $769K | 68,345 |
| 2025-11-13 | Greenstreet Yvonne Chief Executive Officer | Sale 10b5-1 | −1,599 | $452.85 | $724K | 66,746 |
| 2025-11-13 | Greenstreet Yvonne Chief Executive Officer | Sale 10b5-1 | −881 | $453.99 | $400K | 65,865 |
| 2025-11-13 | Greenstreet Yvonne Chief Executive Officer | Sale 10b5-1 | −195 | $454.69 | $89K | 65,670 |
Page 17 of 41 · 816 trades